Aug 25, 2022
GFAP (Glial Fibrillary Acidic Protein) is a type III intermediate filament protein that is expressed by numerous cell types in the central nervous system (CNS), including astrocytes and ependymal cells during development.
GFAP has been shown to be important in the pathogenesis of Alexander disease and in repair after CNS injury. Evidence suggests that minor changes in blood GFAP levels are associated with subtle injuries to the CNS. Decreases in GFAP expression have been reported in Down's syndrome, schizophrenia, bipolar disorder, and depression.
Serum GFAP shows promise as a biomarker of disease severity in frontotemporal lobar degeneration (FTLD) and might be a suitable multiple sclerosis progression biomarkers. In addition, few studies have explored the possibility of blood GFAP levels as a biomarker for traumatic spinal cord injury.
GFAP Resource Tool Center
Assay Kits for GFAPGet your GFAP Elisa Kit here
Antibodies for GFAP
OriGene has developed highly-specific and sensitive antibodies that recognize native epitopes which can be used in IHC, ELISA, WB. IF, IP etc
Immunohistochemical staining of paraffin-embedded Human embryonic brain tissue using anti-GFAP mouse monoclonal antibody.
Immunohistochemical staining of paraffin-embedded Human embryonic brain cortex tissue within the normal limits using anti-GFAP mouse monoclonal antibody.
Primary Antibody Samples
Immunohistochemical staining of paraffin-embedded lymph node tissue using anti-GFAP mouse monoclonal antibody.
Clones for GFAP
OriGene has developed expression ready plasmids and Lentiviral particles for various species such as human, mouse and rat species